Current and novel antibiotics against resistant Gram-positive bacteria

Abstract

The challenge posed by resistance among Gram-positive bacteria, epitomized by methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE) and vancomycin-intermediate and -resistant S. aureus (VISA and VRSA) is being met by a new generation of antimicrobials. This review focuses on the new β-lactams with activity against MRSA (ceftobiprole and ceftaroline) and on the new glycopeptides (oritavancin, dalbavancin, and telavancin). It will also consider the role of vancomycin in an era of existing alternatives such as linezolid, daptomycin and tigecycline. Finally, compounds in early development are described, such as iclaprim, friulimicin, and retapamulin, among others.

Keywords:

• Gram-positive bacteria
• vancomycin
• anti-MRSA cephalosporins
• lipoglycopeptides
• daptomycin
• linezolid
• tigecycline

Acknowledgements

The Veterans Affairs Merit Review Program and the National Institutes of Health (RO1 AI072219) support the work of Dr. Robert A Bonomo. The authors report no conflicts of interest.